BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant financial challenges, including a drastic revenue decline and increased losses. The heavy dependence on clinical trials, regulatory risks, and cash burn further exacerbate concerns. Additionally, management's lack of clarity on revenue guidance and FDA timelines adds uncertainty. Despite the large market potential for BioCosmeceuticals, the absence of clear revenue projections and reliance on partnerships indicate strategic vulnerabilities. The overall sentiment from the call and Q&A is negative, suggesting a strong negative stock price reaction over the next two weeks.
Key Financial Performance
Third quarter 2025 revenues $11,800, a significant decrease from $233,600 in Q3 2024. The decrease was driven by the timing of orders for the developing BioCosmeceutical revenue stream.
Third quarter 2025 loss from operations $3.7 million, compared to $2.3 million in Q3 2024. The increase in loss was not explicitly explained in the transcript.
Third quarter 2025 net loss $3 million or $0.33 per share, compared to $1 million or $0.13 per share in Q3 2024. The increase in net loss was not explicitly explained in the transcript.
Cash, cash equivalents, and marketable securities at the end of Q3 2025 $4.5 million with no outstanding debt. This does not include the gross proceeds of approximately $1.1 million from recent financing completed after the quarter end.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BRTX-100: A novel cell-based therapeutic targeting areas with little blood flow, currently in Phase II clinical trials for chronic lumbar disc disease. Enrollment is accelerating, and the program has received FDA Fast Track designation, potentially enabling an accelerated BLA approval pathway.
ThermoStem: A preclinical cell-based therapy targeting obesity and metabolic disorders using brown adipose tissue-derived stem cells. The program aims to provide an alternative to GLP-1 therapies and has ongoing licensing discussions with a commercial-stage regenerative medicine company.
BioCosmeceuticals: The business is gaining momentum with strengthened commercial infrastructure and leadership. Expected to contribute significantly to revenue in 2026 and beyond.
Global Obesity Market: Projected to exceed $100 billion annually by the end of the decade, driven by demand for GLP-1 therapies. ThermoStem program is positioned to address this demand.
Japanese Patent Approval: Received a notice of allowance for the ThermoStem platform, providing broad protection for brown adipose-derived stem cell technology in U.S. and international markets.
Financial Performance: Q3 2025 revenues were $11,800, a significant decrease from $233,600 in Q3 2024, primarily due to timing of BioCosmeceutical orders. Net loss increased to $3 million from $1 million in the same period last year.
Recent Financing: Raised $1.1 million in gross proceeds post-Q3, strengthening the balance sheet to support clinical and commercial milestones.
Leadership Appointment: Crystal Romano appointed as Global Head of Commercial Operations to drive BioCosmeceuticals' growth.
Licensing Discussions: Ongoing discussions with a regenerative medicine company for licensing the ThermoStem program, with no interim updates provided.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company's third quarter 2025 revenues were significantly lower compared to the same period in 2024, primarily due to the timing of orders for the developing BioCosmeceutical revenue stream. This decline in revenue could impact the company's financial stability and ability to fund operations.
Increased Losses: The company's net loss increased from $1 million in Q3 2024 to $3 million in Q3 2025, indicating worsening financial performance. This could strain resources and limit future investments.
Dependence on Clinical Trials: The company’s lead clinical program, BRTX-100, is still in Phase II trials. Delays or unfavorable outcomes in these trials could significantly impact the company’s strategic objectives and financial performance.
Regulatory Risks: While the BRTX-100 program has received Fast Track designation, there is no guarantee of FDA approval or accelerated pathways, which could delay commercialization and revenue generation.
Supply Chain and Commercial Infrastructure: The company is rebuilding its commercial infrastructure, including supply chain and distribution networks, for its BioCosmeceuticals business. Any disruptions or inefficiencies in this process could hinder revenue growth.
Licensing Agreement Uncertainty: The company is in discussions with a commercial stage Regenerative Medicine Company regarding a potential license agreement for its ThermoStem program. Failure to reach an agreement could limit the program's commercial potential.
Cash Burn and Financing Risks: The company reported a net loss and is relying on recent financing to fund operations. Prolonged cash burn without significant revenue generation could lead to financial instability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
BRTX-100 Clinical Trial: Enrollment in the Phase II BRTX-100 clinical trial for chronic lumbar disc disease is nearing completion. The company anticipates presenting additional data from a larger patient population and expects the results to align with earlier positive trends. A potential Type B FDA meeting in December could discuss an accelerated BLA approval pathway.
ThermoStem Program: The ThermoStem program is focused on developing cell-based therapies for obesity and metabolic disorders. The company is in discussions with a commercial stage Regenerative Medicine Company for a potential licensing agreement. The program aims to address the growing demand for GLP-1 therapies with a regenerative solution and mitigate associated risks. A comprehensive patent portfolio has been developed, including a newly allowed Japanese patent for the ThermoStem platform.
BioCosmeceuticals Business: The BioCosmeceuticals business is expected to contribute significantly to revenue in 2026 and beyond. The company has strengthened its commercial infrastructure and appointed a new Global Head of Commercial Operations to drive scalable revenue growth.
Financial Position and Financing: The company recently completed a fully subscribed financing round priced above market, strengthening its balance sheet. This ensures resources are available to advance clinical and commercial milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk about the significance of the BioCosmeceuticals opportunity and whether you can tap into this market on your own or need more partnerships like Cartessa?
A:The BioCosmeceuticals market is a $63 billion opportunity. The company is positioning itself as a hybrid biotech firm with a differentiated profile. They are approaching the market with a three-pronged strategy: expanding distribution beyond Cartessa, selling directly to med spas and aestheticians, and potentially launching a direct-to-consumer branded product. The company has unique manufacturing capabilities to customize products. However, specific revenue guidance is not yet available, and initial business development may show revenue lumpiness.
Q:How does the focus on BioCosmeceuticals impact the overall business strategy and resource allocation? Are there synergies with the clinical development side?
A:The BioCosmeceuticals program leverages cell lines used for clinical purposes but focuses on topical and cosmetic applications. Resources can be managed with the current team, with potential additions in quality and manufacturing. The program will utilize lab capacity during a lull between Phase II and Phase III clinical trials. Synergies include credibility from being a legitimate biotech company.
Q:When can we expect subsequent data release for BRTX-100? Will it be blinded or final data? Can you provide a numerical enrollment update?
A:The company is more than three-quarters enrolled in the trial, with over 10 patients in late-stage screening. Enrollment completion is expected by year-end or early next year. Data will remain blinded to support regulatory strategy with the FDA, aiming to move directly to a Phase III pivotal study. If two Phase III trials are required, data may be unblinded after a 12-month follow-up.
Q:What is the status of the cervical trial?
A:The cervical trial has an approved protocol with the FDA, but no resources are currently allocated for site and patient recruitment due to financial constraints. The focus remains on the lumbar spine, with the expectation that a BLA approval will enable broader applications in avascular zones.
Q:Will there be BioCosmeceutical revenues in Q4 similar to Q2?
A:There is no clear visibility on Q4 BioCosmeceutical revenues. Some products have been sold since Crystal joined, but the scale is still nascent compared to the potential opportunity.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue guidance for the BioCosmeceuticals program, citing early-stage development and potential revenue lumpiness. They also did not provide a definitive timeline for FDA feedback on the Phase III protocol or clarity on whether one or two Phase III trials will be required for BRTX-100.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BioCosmeceutical sale
BioCosmeceutical stream
BioRestorative President
BioRestorative ThermoStem
CEO afternoon
CFO overview
Chairman President
Conference Instructions
Development Secretary
Director benefit
Enrollment Phase
FDA Type
Fast Track
Francisco VP
GLP injection
GLP therapy
Greetings BioRestorative
II study
Lance Chairman
Medicine regard
Officer Vice
Phase II
President CEO
President Chairman
Regenerative Medicine
Relations afternoon
Results Update
Secretary Director
ThermoStem program
Track designation
Type meeting
Update Conference
cell tissue
demand
designation FDA
end
tissue stem
BRTX Transcript
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals significant financial challenges, including a drastic revenue decline and increased losses. The heavy dependence on clinical trials, regulatory risks, and cash burn further exacerbate concerns. Additionally, management's lack of clarity on revenue guidance and FDA timelines adds uncertainty. Despite the large market potential for BioCosmeceuticals, the absence of clear revenue projections and reliance on partnerships indicate strategic vulnerabilities. The overall sentiment from the call and Q&A is negative, suggesting a strong negative stock price reaction over the next two weeks.
Earnings call transcript: BioRestorative Therapies Q1 2025 sees widened losses
Unknown5-14
The earnings call reveals several concerns: a significant revenue decline, increased net loss, and operational losses, along with uncertainties in clinical trials and market competition. Despite a strong cash position, these issues overshadow positive aspects like the FDA's Fast Track designation and potential patient recruitment improvements. The Q&A section highlights management's unclear responses, particularly regarding interim analysis, adding to investor uncertainty. Given these factors, the stock is likely to experience a negative reaction, reflecting investor concerns over financial performance and strategic execution.
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals several concerning factors: a significant increase in net loss, decreased revenue, and a rise in operational costs. Despite positive deferred revenue and no debt, financial instability is evident. The Q&A section highlights uncertainties, particularly regarding clinical trials and regulatory risks. No share repurchase program is announced, and market competition remains a threat. These factors, combined with the absence of strong positive catalysts, suggest a likely negative stock price movement over the next two weeks.
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call summary shows strong revenue growth and improved financial metrics, but the company still faces significant risks, including regulatory uncertainties and financial losses. The Q&A session highlighted management's cautious responses regarding trial enrollment and cash burn, suggesting potential uncertainties. The lack of a shareholder return plan and the competitive landscape further contribute to a neutral sentiment. Despite positive developments like FDA Fast Track designation, the absence of immediate catalysts and ongoing challenges balance the overall outlook.
BRTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
